About wave life sciences ltd - WVE
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
WVE At a Glance
Wave Life Sciences Ltd.
Marina One East Tower
Singapore, Central Singapore 018936
| Phone | 65-6236-3388 | Revenue | 108.30M | |
| Industry | Biotechnology | Net Income | -97,008,000.00 | |
| Sector | Health Technology | Employees | 288 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
WVE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 15.794 |
| Price to Book Ratio | 9.035 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.17 |
| Enterprise Value to Sales | 13.312 |
| Total Debt to Enterprise Value | 0.018 |
WVE Efficiency
| Revenue/Employee | 376,048.611 |
| Income Per Employee | -336,833.333 |
| Receivables Turnover | 76.162 |
| Total Asset Turnover | 0.345 |
WVE Liquidity
| Current Ratio | 2.888 |
| Quick Ratio | 2.888 |
| Cash Ratio | 2.723 |
WVE Profitability
| Gross Margin | 92.001 |
| Operating Margin | -101.94 |
| Pretax Margin | -89.572 |
| Net Margin | -89.572 |
| Return on Assets | -30.936 |
| Return on Equity | -73.243 |
| Return on Total Capital | -39.955 |
| Return on Invested Capital | -62.979 |
WVE Capital Structure
| Total Debt to Total Equity | 11.686 |
| Total Debt to Total Capital | 10.463 |
| Total Debt to Total Assets | 7.213 |
| Long-Term Debt to Equity | 8.48 |
| Long-Term Debt to Total Capital | 7.317 |